Location History:
- Oakland, CA (US) (2005)
- Davis, CA (US) (2005)
Company Filing History:
Years Active: 2005
Title: Innovations by John M Henstrand: Advancing Enzyme Therapies
Introduction
John M Henstrand is an accomplished inventor based in Oakland, CA, whose contributions to the field of biotechnology have led to significant advancements in enzyme therapies. With a total of two patents to his name, Henstrand focuses on addressing medical conditions associated with enzyme deficiencies, particularly those related to N-acetylgalactosamine-4-sulfatase.
Latest Patents
Henstrand's latest patents center around the precursor of N-acetylgalactosamine-4-sulfatase, detailing methods of treatment using the enzyme and techniques for its production and purification. The inventions provide a highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase, along with biologically active mutants, fragments, and analogs. These inventions are vital for pharmaceutical formulations aimed at treating diseases caused by deficiencies in this enzyme, such as MPS VI. The innovative methods for producing and refining the enzyme are key to improving treatment outcomes for affected patients.
Career Highlights
Henstrand's career is marked by his role at BioMarin Pharmaceutical Inc., where he leverages his expertise to drive research and development initiatives. His work plays a critical role in the company's mission to deliver innovative therapies for patients with serious medical conditions.
Collaborations
Throughout his career, Henstrand has collaborated with notable colleagues, including Minmin Qin and Gary N Zecherle. These partnerships highlight the collaborative spirit in scientific research, where diverse expertise converges to develop groundbreaking solutions.
Conclusion
John M Henstrand stands at the forefront of enzyme therapy innovation, with patents that reflect his commitment to addressing critical health challenges. His work has the potential to positively impact the lives of many individuals suffering from enzyme deficiencies, showcasing the importance of continuous innovation in the field of biotechnology.